Research Chemicals

Sarm LGD-4033

LGD-4033, also known as Ligandrol, is a selective androgen receptor modulator (SARM) developed primarily for treating conditions like muscle wasting, osteoporosis, and age-related muscle loss. It is non-steroidal, meaning it targets androgen receptors in muscle and bone tissue without the broad hormonal effects typical of anabolic steroids. This selectivity is what makes it appealing for clinical and research purposes. Sarms are research chemicals not intended for human consumption.

Mechanism of Action:
LGD-4033 binds to androgen receptors in skeletal muscle and bone tissue, stimulating protein synthesis and muscle growth. Unlike traditional anabolic steroids, it has minimal impact on the prostate, liver, or other androgen-sensitive organs, reducing the risk of many side effects associated with steroid use. Its binding affinity is high, which makes it potent even at low doses.

Potential Benefits:

Muscle growth: Increases lean body mass and strength, making it popular in both clinical research and fitness communities.
Bone density support: May enhance bone strength, which is particularly useful in studies on osteoporosis.
Fat reduction: While not primarily a fat-loss agent, increased muscle mass can contribute to improved metabolism.
Minimal androgenic side effects: Low risk of hair loss, acne, or prostate enlargement compared to anabolic steroids.

Dosage and Administration:
Research typically uses doses ranging from 0.1 mg to 1 mg daily in clinical studies, though anecdotal reports from fitness communities often cite 5–10 mg daily. It is orally bioavailable, so it is taken in pill form. Its half-life is around 24–36 hours, which allows for once-daily dosing.

Side Effects:
While LGD-4033 is generally well-tolerated in research, potential side effects include:

Temporary suppression of natural testosterone production
Mild liver enzyme changes in some cases
Headaches or fatigue in sensitive individuals
Possible increase in LDL cholesterol with long-term use

Detection and Duration:
LGD-4033 can remain detectable in the body for up to 3 weeks after administration, depending on dose and testing methods. It is banned by most sports organizations due to its anabolic potential.

In summary, LGD-4033 is a potent SARM with high anabolic activity in muscle and bone, oral availability, and a favorable safety profile relative to traditional anabolic steroids, though hormonal suppression is a consideration for longer-term use.

Dosing LGD-4033 (Ligandrol) depends on your goals, tolerance, and whether it’s used for research purposes or fitness/anti-aging protocols. Since it is a potent SARM with hormonal effects, careful dosing is important to limit side effects, particularly testosterone suppression.

Typical Dosing Ranges:

Beginner/Low Dose: 2–5 mg per day
Intermediate Dose: 5–10 mg per day
Higher Dose (research/anabolic effect): 10 mg per day or slightly more, though this increases the risk of testosterone suppression

Cycle Length:

Most cycles last 6–8 weeks. Going longer increases the risk of hormonal suppression and other side effects.

Administration:

LGD-4033 is taken orally, usually once per day because it has a half-life of about 24–36 hours.
Some users split the dose into morning and evening to maintain steadier blood levels, but once-daily dosing is common.

Post-Cycle Considerations:

Even at moderate doses, LGD-4033 can suppress natural testosterone. A post-cycle therapy (PCT) may be recommended to help your hormones recover.
Common recovery strategies include selective estrogen receptor modulators (SERMs) like tamoxifen or clomiphene, but the exact need depends on dose and cycle length.

Additional Notes:

Start with a lower dose to gauge tolerance before increasing.
Avoid stacking with other SARMs or anabolic compounds until you understand how your body responds.
Regular blood work is advisable if using for more than a few weeks, especially to monitor testosterone, liver enzymes, and lipid profile.

Here’s a sample LGD-4033 (Ligandrol) cycle designed for muscle growth while trying to minimize side effects and support hormone recovery.

Maintain gains; optional taper to reduce abrupt suppression

Administration:

Take once daily, preferably in the morning with food.
For steadier blood levels, you can split into 2.5 mg morning + 2.5 mg evening, but once-daily is sufficient.

Post-Cycle Therapy (PCT)

Even moderate doses of LGD-4033 can suppress testosterone. A short PCT can help recovery:

Week 1–4

Nolvadex (Tamoxifen)20 mg daily. Helps stimulate natural testosterone recovery

OR Clomid (Clomiphene) 25 mg daily

Alternative to Tamoxifen if preferred

Optional Supplements:

Liver support: Milk thistle or N-acetylcysteine (NAC)
Cardiovascular support: Omega-3s
General recovery: Adequate protein, sleep, and resistance training

Monitoring and Safety Tips

Check blood work 1–2 weeks after cycle completion: testosterone, liver enzymes, lipid profile.
Watch for signs of suppression: low libido, fatigue, mood changes.
Avoid stacking with other SARMs or steroids in the same cycle unless experienced and monitored.

MK-677

MK-677, also called Ibutamoren or Nutrabol, is a non-peptide compound classified as a selective agonist of the ghrelin receptor (GHS-R1a). While often discussed alongside growth hormone (GH) secretagogues or peptides, MK-677 is not a peptide—it’s orally active and functions by stimulating the pituitary gland to increase growth hormone (GH) and insulin-like growth factor 1 (IGF-1) secretion. MK-677 is a research chemical and is not intended for human consumption.

Mechanism of Action:
MK-677 binds to the ghrelin receptor, which mimics the natural hormone ghrelin. Activation of this receptor triggers the pituitary to release more GH. This process leads to higher circulating levels of IGF-1, which mediates many of the anabolic and regenerative effects typically associated with growth hormone. Unlike injectable GH or GH-releasing peptides like CJC-1295 or Ipamorelin, MK-677 does not require injection and has a long half-life of around 24 hours, allowing once-daily oral dosing.

Effects and Benefits:

Muscle Growth: Elevated GH and IGF-1 can promote lean muscle mass accumulation, improved recovery, and enhanced strength when paired with resistance training.
Fat Loss: MK-677 may support fat metabolism, particularly by increasing basal metabolic rate and mobilizing fat stores. Visceral fat reduction is also possible over prolonged use.
Bone Density: GH and IGF-1 play a critical role in bone remodeling; studies indicate MK-677 can increase bone mineral density over time.
Sleep Improvement: Some users report deeper and more restful sleep, likely linked to GH pulsatility during slow-wave sleep.
Skin and Tissue Health: GH and IGF-1 support collagen production, which can improve skin elasticity, wound healing, and overall tissue regeneration.
Anti-Aging Potential: By boosting GH and IGF-1 levels, MK-677 may counteract age-related declines in muscle, bone density, and skin integrity.

Dosing and Administration:
Typical doses range from 10 mg to 25 mg daily, taken orally. Effects are cumulative and generally noticeable after 4–12 weeks of consistent use. Because of its long half-life, splitting doses is not necessary.

Side Effects and Considerations:
While generally well-tolerated, MK-677 can cause:

Increased appetite (a common effect due to ghrelin receptor activation)
Mild water retention or edema
Joint stiffness
Temporary insulin resistance or slight increases in blood sugar
Numbness or tingling in extremities (rare)

Long-term effects are still being studied, particularly regarding insulin sensitivity and cardiovascular health. Monitoring with a healthcare provider is recommended if used for extended periods.

Comparison with Other Growth Hormone Secretagogues:

Unlike CJC-1295 or Ipamorelin, MK-677 is oral rather than injectable.
It produces a sustained elevation of GH, instead of pulsatile bursts.
MK-677 does not require peptides, refrigeration, or daily injections, making it more convenient for some users.

Summary:
MK-677 is a potent oral growth hormone secretagogue that increases GH and IGF-1 levels, supporting muscle growth, fat loss, bone health, and potentially anti-aging effects. It offers a convenient alternative to injectable peptides, though side effects such as increased appetite and water retention should be considered. Long-term safety data are still limited.

MK-677 is typically taken orally once per day, usually in the morning or before bed. Its long half-life of about 24 hours means you don’t need multiple doses.

Typical Dose Range:

Beginner: 5–10 mg per day
Standard/Moderate: 10–20 mg per day
Advanced/Experienced: Up to 25 mg per day

Timing:

Morning: Can reduce the risk of nighttime vivid dreams or sleep disruption for some users.
Before Bed: Some prefer this because MK-677 can enhance deep sleep and GH secretion during slow-wave sleep.

Cycle Length:

Most users run 8–12 week cycles, though some go longer. Effects like improved sleep, muscle growth, or fat loss generally become noticeable after 4–6 weeks.

Important Considerations:

Consistency: Take it at the same time each day for stable blood levels.
Food: Can be taken with or without food.
Side Effects: Watch for increased appetite, mild water retention, or temporary insulin sensitivity changes. Adjust dose if needed.

MK-677 is not typically “stacked” in the same way injectable peptides are, since it already produces sustained GH elevation.

MK-677 Daily Schedule (Example for 10–20 mg/day)

Morning Option

Time: 7–9 AM
Dose: 10–20 mg orally
With/Without Food: Either; taking with food may slightly reduce mild nausea for sensitive users.

Tips:

Take at the same time each day to maintain steady blood levels.
Drink plenty of water to help reduce water retention.
If appetite increases significantly, plan meals/snacks accordingly.

Evening Option (Before Bed)

Time: 30–60 minutes before sleep
Dose: 10–20 mg orally

Tips:

Can improve deep sleep due to GH pulsation enhancement.
Some users experience vivid dreams—start on the lower end if this is concerning.

Weekly Monitoring & Adjustments:

Weeks 1–2: Start at the lower dose (5–10 mg) to assess tolerance.
Weeks 3–4: Increase to standard dose (10–20 mg) if well-tolerated.
Weeks 5–12: Maintain steady dose; monitor appetite, weight, and any mild side effects like water retention.

Cycle Duration:

8–12 weeks is standard for noticeable effects. Some advanced users go longer, but long-term safety data is limited.

Side Effect Management Tips:

Increased appetite: Plan healthy, controlled meals; high-protein snacks can help.
Water retention: Reduce excess sodium; monitor weight weekly.
Joint stiffness or tingling: Stretching, light exercise, or magnesium supplements may help.
Blood sugar changes: Pair with a balanced diet; monitor fasting glucose if at risk for insulin resistance.

Sarm MK-2866

MK-2866, also known as Ostarine or Enobosarm, is a selective androgen receptor modulator (SARM) developed to mimic the effects of anabolic steroids without the broad hormonal side effects. It selectively binds to androgen receptors in muscle and bone tissue, promoting muscle growth and improving bone density, while minimizing impacts on other tissues such as the prostate and liver. Sarms are research chemicals not intended for human consumption.

Mechanism of Action:

MK-2866 works by selectively targeting androgen receptors in skeletal muscle and bone. Upon binding, it stimulates protein synthesis, enhancing muscle mass and strength. Unlike traditional anabolic steroids, it has a lower tendency to convert to estrogen or affect natural testosterone production significantly, though high doses or prolonged use can still cause some suppression.

Benefits:

Muscle Growth: MK-2866 is often used for lean muscle gains, particularly during cutting phases where preserving muscle mass is crucial.
Fat Loss Support: While not directly a fat-burning compound, by increasing lean body mass, it can indirectly improve metabolic rate.
Injury Recovery: Some research suggests MK-2866 may aid in maintaining muscle mass during injury or periods of immobilization.
Bone Health: Studies have shown improvements in bone density, making it potentially beneficial for osteoporosis or age-related muscle loss.

Dosage and Cycle:

Typical dosages for performance purposes range from 10 mg to 25 mg per day, often in cycles of 6 to 12 weeks. Doses beyond 25 mg daily are uncommon and may increase the risk of hormonal suppression or other side effects. Because MK-2866 can suppress natural testosterone at higher doses, post-cycle therapy (PCT) may be considered after longer or higher-dose cycles.

Side Effects:

MK-2866 is generally well-tolerated, but some users may experience-

Mild testosterone suppression at higher doses
Headaches or fatigue
Rarely, slight increases in liver enzymes

Compared to traditional anabolic steroids, MK-2866 carries a significantly lower risk of severe androgenic or estrogenic side effects.

Forms and Administration:

MK-2866 is most commonly available as an oral liquid or capsule, offering convenience compared to injectable compounds. Its half-life is approximately 24 hours, allowing once-daily dosing.

MK-2866 is a versatile SARM valued for its ability to promote lean muscle mass, support recovery, and protect bone health, with a favorable safety profile relative to anabolic steroids. While not completely free from hormonal effects, it offers a targeted approach to muscle and bone health, making it popular in both clinical research and athletic contexts.

Standard Dosing Guidelines:

Typical Range: 10–25 mg per day
Common Cycle Length: 6–12 weeks
Frequency: Once daily, usually taken in the morning with or without food
Starting Dose: Many users start at 10–15 mg per day for the first week to assess tolerance.

Muscle Maintenance / Mild Gains:

Dose: 10–15 mg per dayCycle: 6–8 weeks
Best for cutting phases or preventing muscle loss during calorie deficits

Moderate Muscle Growth / Strength Gains:

Dose: 15–20 mg per dayCycle: 8–12 weeks
Often used during bulking cycle.

Aggressive Muscle Gains (Advanced / Higher Risk of Suppression):

Dose: 20–25 mg per day

Cycle: 8–12 weeks
Higher doses can increase testosterone suppression, so post-cycle therapy (PCT) is sometimes recommended

Post-Cycle Therapy (PCT):

MK-2866 can suppress natural testosterone at higher doses or longer cycles.
If your cycle is moderate (20 mg/day for 8 weeks), many users report minimal suppression.
For longer or higher-dose cycles, a short PCT of 2–4 weeks may help restore natural hormone levels.

Additional Tips:

Timing: Once-daily dosing is sufficient due to MK-2866’s 24-hour half-life.
Stacking: It’s often stacked with other SARMs or peptides depending on goals, but combining compounds increases the need for careful monitoring of hormonal effects.
Monitoring: Bloodwork before and after cycles is strongly recommended to track testosterone, liver enzymes, and lipid profiles.

PCT Options:

Mild (for beginners): Light supplements, natural testosterone support (zinc, vitamin D, D-aspartic acid)
Moderate/Advanced: Use selective estrogen receptor modulators (SERMs) like Nolvadex (tamoxifen) or Clomid (clomiphene) if suppression occurs
Bloodwork: Recommended for intermediate and advanced users before and after the cycle

Additional Guidelines:

Timing: Once daily, preferably in the morning
Stacking: Can be combined with other SARMs, but monitor hormonal effects
Diet & Training: Lean muscle gains require adequate protein intake and resistance training
Hydration & Sleep: Crucial for recovery and hormone balance

5-Amino-1MQ

5-Amino-1MQ is a synthetic small molecule that inhibits the enzyme nicotinamide N-methyltransferase (NNMT), which is primarily active in fat tissue and associated with obesity and metabolic dysfunction. By blocking NNMT, 5-Amino-1MQ helps increase levels of nicotinamide adenine dinucleotide (NAD+), a coenzyme crucial for cellular metabolism. Elevated NAD+ activates sirtuin-1 (SIRT1), often referred to as the "longevity gene," which plays a role in DNA repair, inflammation reduction, and metabolic regulation.

Mechanism of Action:

NNMT catalyzes the transfer of a methyl group from S-adenosylmethionine (SAM) to nicotinamide, producing 1-methylnicotinamide (1-MNA). This process consumes methyl donors and depletes NAD+ levels. By inhibiting NNMT, 5-Amino-1MQ prevents this depletion, thereby preserving NAD+ and supporting mitochondrial function and energy production .

Benefits:

Fat Loss: In animal studies, 5-Amino-1MQ has been shown to reduce fat cell size and volume, decrease cholesterol levels, and promote fat oxidation without affecting appetite or food intake .
Muscle Preservation: By increasing NAD+ and activating SIRT1, 5-Amino-1MQ supports muscle maintenance during fat loss, making it suitable for body recomposition goals .
Energy and Performance: Enhanced mitochondrial function leads to improved energy production, which can boost physical performance and recovery .
Anti-Aging Effects: Activation of SIRT1 may contribute to cellular repair and longevity, potentially slowing aspects of the aging process .

Usage and Availability:

5-Amino-1MQ is typically administered in oral capsule form, with dosing regimens varying based on individual health goals. It is often used in cycles of 4–8 weeks under medical supervision . The compound is not approved by the U.S. Food and Drug Administration (FDA) for human use and is generally available only for research purposes. Athletes should be aware that it is classified under the World Anti-Doping Agency's S0 category, indicating that it is prohibited in competition .

Considerations:

While 5-Amino-1MQ shows promise in preclinical studies, human clinical trials are limited. Its long-term safety and efficacy have not been established. Individuals interested in this compound should consult with a healthcare provider to assess potential risks and benefits.

Dosing 5-Amino-1MQ effectively requires careful attention to timing, dosage, and cycling to maximize benefits and minimize potential side effects. Here's a comprehensive guide based on current protocols and expert recommendations:

Standard Dosage Guidelines:

Typical Daily Dose: 50–100 mg, often split into two doses (e.g., 25–50 mg twice daily) to maintain stable blood levels .
Starting Dose: Begin with 50 mg per day to assess tolerance. If well-tolerated, gradually increase to 75 mg, and potentially up to 100 mg per day .
Timing: Administer in the morning and early afternoon, especially if combined with fat burners or other peptides that influence energy and metabolism .

Cycling Protocol:

Cycle Length: Common cycles last 4–6 weeks, followed by a 2–4 week break to allow the body to stabilize NAD+ metabolism and avoid unnecessary adaptation or receptor downregulation .
Break Period: During off-cycles, the body can reset, enhancing the effectiveness of subsequent cycles .

Administration Method:

Oral Capsules: Swallow the capsule whole with a glass of water; do not chew or crush the capsule .
Injection (Alternative Method): Subcutaneous injections are typically administered at 50–100 mg daily, with some protocols suggesting split dosing (e.g., 50 mg in the morning and 50 mg in the afternoon) .

Safety and Considerations:

Consultation: Always consult a healthcare provider before starting 5-Amino-1MQ, especially if you have pre-existing medical conditions or are taking other medications .
Monitoring: Regular monitoring is advised to assess effectiveness and adjust dosing as needed .

By adhering to these guidelines, you can optimize the benefits of 5-Amino-1MQ while minimizing potential risks.

1. Daily Dose:

Most protocols use 50–100 mg per day.
Often split into two doses (morning and early afternoon) to maintain stable blood levels.
Start at the lower end (50 mg/day) to assess tolerance before increasing.

2. Cycle Length:

Standard cycles last 4–6 weeks.
Followed by a 2–4 week break to allow the body to reset NAD+ metabolism.

3. Administration:

Oral capsules: swallow whole with water.
Injectable form (less common): subcutaneous injection, split dosing of 50–100 mg daily.

4. Safety Considerations:

Always consult a healthcare provider before starting.
Monitor for effects and adjust dosing if necessary.
Note that this compound is for research purposes and is not FDA-approved for human use.

Sarm AC-262

AC-262, also known as AC-262536, is a selective androgen receptor modulator (SARM) developed primarily for research into conditions related to muscle wasting, osteoporosis, and other degenerative muscle disorders. It’s part of a class of compounds designed to provide the anabolic (muscle-building) benefits of traditional anabolic steroids, but with more tissue specificity and fewer androgenic (masculinizing) side effects. Sarms are research chemicals and not intended for human consumption.

Mechanism of Action:
AC-262 binds selectively to androgen receptors in muscle and bone tissues. Once bound, it stimulates protein synthesis and promotes muscle growth, similar to testosterone, but with reduced impact on organs like the prostate. Its selective nature aims to minimize the unwanted androgenic effects commonly associated with steroid use, such as hair loss, acne, or prostate enlargement.

Potential Benefits:

Muscle growth and improved lean body mass.
Potential support for bone density and strength, making it of interest in osteoporosis research.
Possible aid in recovery from muscle-wasting conditions, such as sarcopenia or cachexia.

Pharmacokinetics:
Research on AC-262 is limited compared to more well-known SARMs like Ostarine (MK-2866). Animal studies suggest good oral bioavailability and the ability to achieve anabolic effects at relatively low doses. Human data is very scarce, so precise dosing, half-life, and metabolism are not well-established.

Side Effects and Risks:
Because human research is minimal, safety data is largely unknown. Animal studies indicate a lower risk of liver toxicity and androgenic side effects compared to traditional anabolic steroids, but long-term effects are uncertain. Potential risks may include hormonal suppression, cholesterol changes, or unknown cardiovascular effects.

Forms and Administration:
AC-262 is typically used as an oral compound in research settings. It’s rarely found in legitimate clinical trials and is mainly restricted to experimental use. There are no approved medical formulations for humans.

Legal Status:
AC-262 is not FDA-approved for medical use. It is classified as a research chemical and is often marketed in the supplement or experimental research space. Sale for human consumption is generally illegal in many countries.

AC-262536 (AC-262) has extremely limited human research, so there is no officially established safe or effective dose for humans. Most of the information available comes from animal studies, and extrapolating to humans carries significant uncertainty. Any “dosing” circulating online is speculative and based on anecdotal reports from the research chemical community.

Sarm RAD-140

RAD-140, also known as Testolone, is a selective androgen receptor modulator (SARM). It was developed to mimic the effects of anabolic steroids by binding to androgen receptors, primarily in muscle and bone tissue, while minimizing activity in tissues like the prostate. This selective mechanism aims to provide muscle-building and fat-reducing benefits with fewer androgenic side effects compared to traditional steroids. Sarms are research chemicals not intended for human consumption.

Mechanism of Action:
RAD-140 binds strongly to androgen receptors in skeletal muscle and bone. By activating these receptors, it promotes anabolic activity—essentially stimulating protein synthesis and muscle growth. Unlike testosterone, it has less impact on the prostate and other androgen-sensitive organs, which reduces the risk of certain side effects such as prostate enlargement. It also shows potential neuroprotective effects in preliminary studies.

Potential Benefits:

Muscle growth: RAD-140 is highly anabolic, promoting lean muscle mass even at relatively low doses.
Fat loss: By increasing lean body mass, it may indirectly support fat reduction. Some users report improved body composition.
Bone health: Preclinical studies suggest it could strengthen bone density.
Cognitive support: Early research indicates RAD-140 might protect neurons, though this is not fully verified in humans.
Recovery: Users often report faster recovery after workouts, likely due to anabolic activity.

Dosage and Administration:
Typical experimental or research-based dosing ranges from 10 mg to 30 mg per day orally. Cycle lengths usually range from 6 to 12 weeks. RAD-140 has a relatively long half-life, around 16–20 hours, allowing for once-daily dosing.

Side Effects and Risks:
While RAD-140 is considered selective, it is not free from risks:

Hormonal suppression: RAD-140 can suppress natural testosterone production, sometimes significantly, depending on dose and cycle length. Post-cycle therapy (PCT) is often recommended.
Liver toxicity: Generally considered low-risk for hepatotoxicity, but liver function should still be monitored.
Other effects: Some users report mild fatigue, headaches, or nausea. Long-term safety data in humans is limited.

Research Status:
RAD-140 is still classified as an experimental compound and is not approved by the FDA for human use. Most human data comes from anecdotal reports or limited clinical trials, so caution is advised.

RAD-140 is a potent, selective androgen receptor modulator designed to provide anabolic benefits similar to testosterone with fewer androgenic effects. It’s popular among researchers and bodybuilders for lean muscle gain and fat reduction, but its long-term safety is not fully established. Hormonal suppression and other risks mean careful monitoring is important if used.

Typical Dosing Range:

Low dose: 5–10 mg per day
Moderate dose: 10–20 mg per day
High dose: 20–30 mg per day

Cycle Length:

Most common cycles last 6–12 weeks.
Longer cycles increase the risk of testosterone suppression and other side effects.

Administration:

RAD-140 is taken orally, usually in liquid or capsule form.
Because of its half-life (~16–20 hours), once-daily dosing is usually sufficient. Some users split the dose into morning and evening to maintain steadier blood levels.

Post-Cycle Therapy (PCT):

RAD-140 suppresses natural testosterone production, sometimes significantly at higher doses or longer cycles.
After a 6–12 week cycle, a PCT protocol using compounds like clomiphene citrate (Clomid) or tamoxifen (Nolvadex) is commonly recommended to restore natural testosterone.

Other Notes:

Beginners often start at the lower end (5–10 mg/day) to assess tolerance.
Liver function and lipid levels may be monitored if cycles are extended or high doses are used.

Here’s a sample RAD-140 cycle based on common research and anecdotal protocols. This is strictly for educational purposes:

Sample RAD-140 Cycle (Beginner to Intermediate)

Cycle Length: 8 weeks
Dosing:

Weeks 1–2: 10 mg per day (start low to assess tolerance)
Weeks 3–8: 15–20 mg per day, taken once in the morning

Administration:

Take RAD-140 orally, ideally on an empty stomach for better absorption.
If splitting the dose, take half in the morning and half in the evening.

Monitoring:

Watch for signs of hormonal suppression: low libido, fatigue, mood changes.
Optional bloodwork: testosterone, liver enzymes, lipid profile.

Post-Cycle Therapy (PCT):

Start PCT 1–2 days after last RAD-140 dose
Clomiphene citrate (Clomid): 50 mg per day for 4 weeks
or Tamoxifen (Nolvadex): 20 mg per day for 4 weeks

Notes:

Beginners should avoid exceeding 20 mg/day.
Cycle length beyond 12 weeks increases suppression risk.
Adequate sleep, nutrition, and training are essential to maximize benefits.

SR-9009

SR-9009, often referred to as Stenabolic, is a synthetic compound developed by Professor Thomas Burris at Scripps Research Institute. It is not a SARM (Selective Androgen Receptor Modulator), even though it is frequently marketed alongside them. Instead, SR-9009 is a REV-ERBα agonist, which means it binds to and activates the REV-ERBα protein, a key regulator of circadian rhythm and metabolic processes.

Mechanism of Action:

REV-ERBα Activation: REV-ERBα is a nuclear receptor involved in the regulation of genes that control circadian rhythm, lipid and glucose metabolism, and energy expenditure.
Increased Mitochondrial Activity: By activating REV-ERBα, SR-9009 enhances mitochondrial function in skeletal muscle. This increases the efficiency of energy production and utilization.
Metabolic Effects: It shifts the body toward using more fatty acids as fuel, while reducing fat storage and improving glucose tolerance.

Potential Benefits (based on preclinical studies):

Fat Loss
Promotes higher energy expenditure, even at rest.
Encourages the body to burn stored fat for energy.
Animal studies show reduced fat mass without changes in diet or exercise.

Endurance and Stamina:
Increases oxidative capacity of muscles, allowing them to perform for longer without fatigue.
Sometimes described as creating an “exercise in a pill” effect because of its impact on aerobic performance.

Glucose and Lipid Regulation:

Improves insulin sensitivity.
Lowers triglycerides and LDL cholesterol.
May help prevent diet-induced obesity and metabolic syndrome.
Circadian Rhythm Support
REV-ERBα plays a major role in regulating the body’s biological clock.
SR-9009 can influence sleep-wake cycles, although this effect has not been studied extensively in humans.

Pharmacokinetics

Oral Bioavailability: Very poor. SR-9009 degrades quickly when taken orally, which is one of the biggest limitations. This is why researchers often experiment with injectable solutions instead, as the oral route has questionable effectiveness.

Half-Life: Short, around 2–4 hours, requiring multiple doses per day if used consistently.

Research Status:

SR-9009 has only been studied in animals and in vitro.
No approved human clinical trials exist to confirm its safety, efficacy, or ideal dosing.
Most data comes from studies on mice, where results showed strong improvements in metabolism, endurance, and fat reduction.

Side Effects and Safety Concerns:

Unknown in Humans: Since it hasn’t undergone clinical testing, the full safety profile is not established.

Possible Concerns:

Liver strain, since it alters metabolic pathways.
Hormonal effects related to circadian disruption.
Short half-life requiring frequent dosing, which may stress the system.

Practical Use

In the performance-enhancement community, SR-9009 is sometimes used as a cutting agent for fat loss or as an endurance booster, though this is entirely experimental and not supported by medical approval.
Injectable formulations are more common among experimenters, given the oral bioavailability issue.

Summary:

SR-9009 (Stenabolic) is a synthetic REV-ERBα agonist designed to manipulate the body’s circadian and metabolic functions. It has shown promise in animal studies for fat loss, endurance, and metabolic health, but it lacks human trials and is not approved for medical use. While it is often marketed as a SARM, it operates through a completely different pathway, making it more of a metabolic regulator than a muscle-building agent.

Typical Research Community Protocols:

Dosage Range
Commonly cited doses: 10–30 mg per day.
Divided into 2–3 doses per day because SR-9009 has a very short half-life (2–4 hours).

Timing:

Usually taken in the morning and early afternoon to align with circadian rhythm effects.
Some users may add a pre-workout dose if endurance or energy is a goal.
Cycle Length
Anecdotal cycles range 4–8 weeks.
Longer cycles are generally avoided due to lack of safety data.

Administration:

Oral capsules are common but poorly absorbed.
Injectable solutions are preferred in research contexts because they bypass the oral bioavailability problem.

Important Notes

There is no standardized or clinically tested dose for humans.
Effects on humans are unknown; long-term safety is unstudied.
SR-9009 should not be considered safe for recreational use.

Additional Tips (Anecdotal Reports):

Take doses on an empty stomach if using oral form to improve absorption.
Monitor for unusual fatigue, insomnia, or digestive issues.
Short half-life means effects may wear off quickly; spacing doses evenly helps maintain more consistent activity.
Many users avoid night-time dosing to prevent potential circadian rhythm disruption.

Bromantane

Bromantane, also known by name Ladasten, is a synthetic compound developed in Russia in the late 1980s. It is classified as an actoprotector, meaning it enhances physical performance and resistance to stress without the typical stimulant side effects. Unlike traditional stimulants, Bromantane is known for promoting both mental and physical endurance while maintaining a calming, anti-anxiety effect.

Mechanism of Action:
Bromantane works through several pathways:

Dopaminergic and Serotonergic Modulation: Bromantane increases the release and availability of dopamine and serotonin in the brain, enhancing mood, motivation, and cognitive performance.
Adaptogenic Properties: It helps the body resist physical and mental stress by modulating stress hormones and improving energy metabolism at the cellular level.
Mitochondrial Support: Some research suggests Bromantane may enhance mitochondrial function, improving cellular energy production, which can boost both endurance and recovery.
Subtle Stimulant Effect: Unlike caffeine or amphetamines, Bromantane increases alertness and energy without causing jitteriness or a crash afterward.

Effects and Benefits:

Physical Performance: Increased endurance, stamina, and resistance to fatigue.
Cognitive Enhancement: Improved focus, attention, mental clarity, and reaction time.
Mood Support: Reduced anxiety and increased motivation, often described as a “calm energy.”
Recovery: Supports faster physical and mental recovery after stress or exercise.

Dosage and Administration:

Typical doses range from 50–100 mg per day, often divided into one or two doses.
Effects usually develop gradually, with maximum benefits often seen after several days of consistent use.
It is generally administered orally in capsule or tablet form.

Safety and Side Effects:

Bromantane is considered low-risk compared to traditional stimulants, with minimal side effects reported.
Mild side effects may include insomnia if taken late in the day, mild headaches, or slight gastrointestinal discomfort.
It does not typically induce tolerance or dependence when used responsibly.

Legal Status:

In Russia, Bromantane is approved for medical use as an anxiolytic and actoprotector.
Its status in other countries varies; in some regions, it is considered a research chemical and is not approved for medical use.

Summary:
Bromantane is a unique compound that combines mild stimulant, anxiolytic, and adaptogenic properties. It enhances both physical and cognitive performance while maintaining a calm, stable effect on mood, making it popular among athletes, biohackers, and individuals seeking stress resilience and mental clarity without the drawbacks of conventional stimulants.

Typical Dosage Range:

Standard dose: 50–100 mg per day.
Frequency: Usually taken once or twice daily, depending on personal tolerance and desired effect.

Timing Recommendations:

Morning or early afternoon: Because Bromantane can increase alertness, taking it late in the day may interfere with sleep.
Split dosing: For some users, splitting the dose (e.g., 50 mg in the morning and 50 mg early afternoon) helps maintain stable effects throughout the day.

Cycle Length:

Bromantane is usually taken for short cycles of 1–4 weeks. Many users report that effects accumulate over several days, so consistent dosing is important.
Unlike traditional stimulants, long-term use does not seem to cause significant tolerance, but breaks are recommended to avoid any unforeseen effects.

Starting Low:

If you are new to Bromantane, starting at 25–50 mg per day is often advised. You can then gradually increase to the full 50–100 mg range if needed.

Important Notes:

Avoid combining with other stimulants unless experienced and aware of potential interactions.
Effects are generally subtle; it is more about steady, calm energy and mental clarity rather than a strong “rush.”

Dihexa

Dihexa is a synthetic peptide developed by researchers at Washington State University, originally designed to treat neurodegenerative conditions like Alzheimer's disease. It is a modified derivative of angiotensin IV, a component of the renin-angiotensin system involved in blood pressure regulation and, intriguingly, cognitive function. Dihexa was engineered to cross the blood-brain barrier effectively and promote synaptic connectivity in areas of the brain responsible for learning and memory—most notably, the hippocampus and cortex.

Mechanism of Action:

Dihexa functions as a hepatocyte growth factor (HGF) mimetic. It binds to the c-Met receptor, activating signaling pathways that promote synapse formation, neuroplasticity, and long-term potentiation—the basis of learning and memory . This process stimulates the formation of new synapses and spines in the hippocampus, much like HGF .

Key Benefits:

Enhanced Neurogenesis: Stimulates the creation of new neurons at a rate seven times greater than brain-derived neurotrophic factor (BDNF), a protein vital for neuron survival and growth .
Cognitive Enhancement: Improves memory formation and recall, learning capacity, mental clarity, and processing ability .
Neuroprotection: Protects neurons from apoptosis, suggesting potential applications in the treatment of neurodegenerative diseases such as Alzheimer's and Parkinson's disease .

Safety and Considerations:

While short-duration safety studies have uncovered no apparent toxicity, the long-term safety of Dihexa remains unstudied. Theoretical concerns exist regarding its mechanism of action, as activation of HGF and c-Met is a key signaling pathway in many cancers . No studies have tested the long-term safety of Dihexa treatment, including its potential effects on tumorigenesis and cancer progression .

Clinical Development:

Fosgonimeton, a pro-drug of Dihexa, is currently in clinical trials for the treatment of neurodegenerative diseases such as Alzheimer's and Parkinson's disease .

Summary:

Dihexa is a potent peptide with the potential to enhance cognitive function and support brain health by promoting neurogenesis and protecting existing brain cells. However, due to limited long-term safety data, its use should be approached with caution. Further research is needed to fully understand its efficacy and safety profile.

Dihexa dosing varies based on individual needs, goals, and the method of administration. While human clinical data are limited, several protocols have emerged from clinical practices and anecdotal reports. Here's a breakdown:

Oral Administration:

Starting Dose: 8–10 mg per day
Titration: Up to 20–40 mg per day, depending on individual tolerance and goals
Cycle Duration: Typically 30–90 days, followed by a break period to prevent tolerance development
Form: Capsules or tablets

Oral administration is the most common method, offering convenience and effective blood-brain barrier penetration.

Transdermal (Cream) Application:

Starting Dose: 10 mg per day
Administration: Applied directly to the skin
Cycle Duration: Similar to oral administration, with breaks as needed

This method provides an alternative for those who prefer not to take oral supplements.

Injectable Administration:

Dosage: 0.5 mg/kg/day
Administration: Intraperitoneal or subcutaneous injection
Cycle Duration: Varies based on clinical indications

Injectable forms are typically used in clinical settings and may offer higher bioavailability.

Important Considerations:

Medical Supervision: Always use Dihexa under the guidance of a healthcare provider trained in peptide therapy.
Side Effects: Potential side effects may include mild headaches, sleep disturbances, or digestive discomfort.
Long-Term Use: Due to limited long-term data, it's advisable to use Dihexa in cycles with breaks to assess effectiveness and minimize potential risks.
Contraindications: Individuals with a history of cancer or those currently undergoing cancer treatment should avoid Dihexa unless under strict clinical supervision.

Given the potency of Dihexa and the variability in individual responses, starting with a lower dose and gradually increasing, if well-tolerated, is generally recommended. Regular consultations with a healthcare provider are essential to tailor the dosing regimen to your specific needs and to monitor for any adverse effects.

Oral (Capsules/Tablets)

Starting Dose: 8–10 mg/day
Titration: Up to 20–40 mg/day based on tolerance and goals
Cycle: 30–90 days, followed by a break
Notes: Convenient, crosses the blood-brain barrier effectively

Transdermal (Cream)

Starting Dose: 10 mg/day applied to the skin
Cycle: Similar to oral dosing
Notes: Alternative for those avoiding oral intake

Injectable (Subcutaneous)

Dose: Around 0.5 mg/kg/day
Cycle: Determined by clinical guidance
Notes: Higher bioavailability, usually under medical supervision

Safety Considerations

Use under guidance of a healthcare provider familiar with peptides
Possible side effects: mild headaches, sleep changes, digestive discomfort
Long-term safety is not established; cycling with breaks is recommended
Avoid if you have a history of cancer unless supervised clinically

The general rule is to start low, monitor effects, and adjust slowly, always under professional supervision.

GW-50516

GW-50516, more commonly known as GW-501516 or Cardarine, is a synthetic compound that acts as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. Developed in the 1990s through a collaboration between Ligand Pharmaceuticals and GlaxoSmithKline, it was initially researched for its potential to treat metabolic and cardiovascular diseases, including obesity, diabetes, and dyslipidemia. However, animal studies revealed that high doses of GW-501516 led to rapid cancer development in multiple organs, prompting its discontinuation in clinical trials in 2007 . This is a research chemical and is not intended for human consumption.

Mechanism of Action:

GW-501516 functions by activating PPARδ receptors, which are predominantly found in skeletal muscle and adipose tissue. This activation shifts the body's energy metabolism from glucose to fatty acids, enhancing fat oxidation and improving endurance. As a result, it has been shown to increase energy expenditure, aid in fat loss, and enhance physical performance in animal models .

Purported Benefits:

While human studies are limited, GW-501516 has been associated with several potential benefits:

Enhanced Endurance: By improving fat utilization, it may increase stamina and reduce fatigue during prolonged physical activity.
Fat Loss: The shift in energy metabolism can lead to accelerated fat burning, contributing to weight loss.
Improved Recovery: Some users report quicker recovery times between workouts, possibly due to enhanced oxygen utilization and reduced muscle damage.
Muscle Preservation: By promoting fat oxidation, it may help preserve lean muscle mass during weight loss phases .

Safety Concerns and Legal Status

The most significant concern with GW-501516 is its potential to cause cancer. Animal studies have shown that prolonged use can lead to the development of tumors in various organs. As a result, the World Anti-Doping Agency (WADA) added GW-501516 to its list of banned substances in 2009 . Additionally, some studies have suggested potential liver damage associated with its use .

Conclusion

GW-501516, or Cardarine, is a compound that has garnered attention for its potential to enhance physical performance and promote fat loss. However, due to significant safety concerns, particularly the risk of cancer, its use is not recommended. Individuals should be cautious and consult healthcare

GW-501516 (Cardarine) does not have an officially approved medical dose because it was never approved for human use due to safety concerns. Most information on dosing comes from animal studies and anecdotal reports in the fitness community, which carries significant risk.

Common anecdotal dosing (not medically recommended):

Typical ranges reported are 10–20 mg per day, often split into one or two doses.
Cycle length is often 6–12 weeks, followed by a break, though longer use in studies caused cancer in animals.

Important safety notes:

There is no safe human dose established. Animal studies showed that long-term exposure caused rapid tumor development.
It is banned by WADA and other sports organizations.
Potential side effects include liver stress, metabolic changes, and cancer risk.

In short, any use of GW-501516 carries serious health risks. Even low doses are not guaranteed to be safe, so medical supervision is crucial if someone is considering it.

1. Exercise-Based Approaches

High-intensity interval training (HIIT): Boosts fat oxidation and endurance.
Steady-state cardio: Long, moderate-intensity sessions improve mitochondrial efficiency and fat metabolism.
Resistance training: Preserves lean muscle while aiding fat loss.

2. Nutritional Strategies

Timed carbohydrate intake: Eating carbs around workouts can enhance endurance without excess fat gain.
Intermittent fasting: Can improve fat utilization and metabolic flexibility.
Omega-3 fatty acids: Support mitochondrial function and fat oxidation.

3. Supplements with Evidence-Based Benefits

Caffeine: Improves stamina and fat oxidation during exercise.
L-Carnitine: Supports the transport of fatty acids into mitochondria for energy production.
Green tea extract (EGCG): Can enhance fat metabolism and support endurance.
Creatine: While primarily for strength, it indirectly supports energy efficiency in high-intensity efforts.

4. Peptides and Hormone Modulators (Safer Options)

MK-677 (Ibutamoren): Stimulates growth hormone and can improve fat metabolism and lean mass preservation.
Tesamorelin: Helps reduce visceral fat in certain populations, especially when combined with diet/exercise.
CJC-1295 with/without DAC & Ipamorelin: Support lean mass, recovery, and metabolic health.

NSI-189

NSI-189 is an experimental nootropic and neurogenic compound developed by Neuralstem, primarily studied for its potential in treating major depressive disorder (MDD) and cognitive impairment. Its chemical name is (benzylpiperizine)nicotinamide, and it is classified as a small-molecule hippocampal neurogenic agent. Unlike traditional antidepressants, which usually target monoamine neurotransmitters like serotonin or dopamine, NSI-189 is thought to work by promoting neurogenesis, the growth and proliferation of new neurons in the hippocampus—a brain region crucial for memory, mood regulation, and learning.

Mechanism of Action:
NSI-189 appears to stimulate the proliferation of neural stem cells in the hippocampus. By increasing hippocampal volume and enhancing neural connectivity, it may improve cognitive function and alleviate depressive symptoms. Preclinical studies in rodents demonstrated enhanced neurogenesis and improved performance on learning and memory tasks, suggesting potential cognitive enhancement effects.

Clinical Research:
NSI-189 has been evaluated in early-phase clinical trials for depression and cognitive impairment associated with MDD. Phase 1 and Phase 2 trials reported that the compound was generally well-tolerated, with mild side effects such as headache, nausea, and fatigue. Some patients showed modest improvement in depressive symptoms and cognition, though results were variable and larger trials are needed to confirm efficacy.

Potential Benefits:

Antidepressant effects without directly targeting monoamines
Cognitive enhancement, particularly in memory and learning
Potential neuroprotective effects due to hippocampal regeneration
May support mood stabilization and resilience against stress

Limitations and Considerations:

Still experimental, not approved by the FDA for clinical use
Long-term safety and efficacy data are lacking
Effects may vary significantly between individuals
Mechanism of neurogenesis in humans is not fully understood

Forms and Dosage:
In research studies, NSI-189 has been administered orally, often in capsule form, with doses ranging between 40 mg to 80 mg per day for up to 28 days. Because it is experimental, there is no standardized therapeutic dosing or guideline for general use.

In summary, NSI-189 is an experimental neurogenic compound with promising but preliminary evidence for mood improvement and cognitive enhancement. Its primary appeal lies in stimulating hippocampal growth rather than altering neurotransmitter levels directly, positioning it as a novel approach to depression and cognitive dysfunction.

NSI-189 is still an experimental compound, so there is no officially approved dosing protocol. The dosing information we have comes from early clinical trials, mostly Phase 1 and Phase 2 studies for depression. Here’s a detailed breakdown based on those studies:

1. Typical Clinical Trial Dosing:

Oral administration: Usually in capsule form
Doses tested: 40 mg, 40 mg twice daily (80 mg/day), and 40 mg three times daily (120 mg/day)
Duration: Typically 28 days in most studies, though some trials went slightly longer

2. Observations from Trials:

The compound was generally well-tolerated at all doses.
Most reported side effects were mild, including headache, nausea, fatigue, or mild gastrointestinal upset.
There was no clear dose-response relationship in terms of efficacy, though higher doses were generally safe.

3. Key Points to Consider:

There is no established therapeutic dose, so using it outside of a clinical trial is experimental and carries unknown long-term risks.
NSI-189’s effects may take weeks to appear, as neurogenesis is a gradual process.
Because it targets hippocampal growth, abrupt changes in dosing are not likely to produce immediate effects.

Disclaimer

The information provided above is not intended to substitute medical advice, diagnosis, or treatment. Should you have any questions regarding a medical condition, seek the advice of your physician or a qualified healthcare provider. In no case should medical advice be disregarded or delayed because of what you have read or seen.